Altheome
Assay Development & ScreeningProtein Sciences & ReagentsPK/PD & ModelingOncologyHematologySmall MoleculePeptide
Quick answer
Outsourcing a hematology program means finding CRO and CDMO partners fluent in blood and bone-marrow biology: disease-specific in vitro and in vivo models, flow cytometry and MRD assays, hematology-trained clinical operations, and access to patients in leukemia, lymphoma, myeloma, or rare bleeding and red-cell disorders. BioBridgeX is a neutral marketplace where buyers source and compare qualified hematology suppliers free, in one place.
Hematology CRO and CDMO vendors (65)
UNIQ Trials
PK/PD & ModelingBioanalytical ServicesIND / Regulatory Package AuthoringOncologyHematologySmall MoleculePeptide
Apeloa Pharmaceutical
Target ID & ValidationAssay Development & ScreeningHit IdentificationOncologyHematologySmall MoleculePeptide
VCHP Clinical Solutions
Computational / AI-Driven DiscoveryPK/PD & ModelingPhase 1 / Early Clinical UnitOncologyHematologySmall MoleculePeptide
AAPharmaSyn
Hit IdentificationHit-to-LeadLead OptimizationOncologyHematologySmall MoleculeRadiopharmaceutical / Radioligand
Symbiosis Pharmaceutical Services
Unclaimed · public records
CDMO · Aseptic Fill-Finish, Drug Product Manufacturing, QC & Release Testing
Aseptic Fill-FinishDrug Product ManufacturingQC & Release TestingOncologyRare / Orphan DiseaseMonoclonal Antibody (mAb)Antibody-Drug Conjugate (ADC)
LOTTE BIOLOGICS
Unclaimed · public records
CDMO · Drug Substance: Biologics, ADC / Bioconjugation, Cell Line / Strain Development
Drug Substance: BiologicsADC / BioconjugationCell Line / Strain DevelopmentOncologyHematologyMonoclonal Antibody (mAb)Antibody-Drug Conjugate (ADC)
BSP Pharmaceuticals
Unclaimed · public records
CDMO · ADC / Bioconjugation, Aseptic Fill-Finish, Drug Product Manufacturing
ADC / BioconjugationAseptic Fill-FinishDrug Product ManufacturingOncologyHematologyAntibody-Drug Conjugate (ADC)Monoclonal Antibody (mAb)
MilliporeSigma (SAFC)
Unclaimed · public records
CDMO · ADC / Bioconjugation, Drug Substance: Small Molecule / API, Process Development
ADC / BioconjugationDrug Substance: Small Molecule / APIProcess DevelopmentOncologyHematologyAntibody-Drug Conjugate (ADC)Monoclonal Antibody (mAb)
WuXi XDC
Unclaimed · public records
CDMO · ADC / Bioconjugation, Drug Substance: Biologics, Drug Substance: Small Molecule / API
ADC / BioconjugationDrug Substance: BiologicsDrug Substance: Small Molecule / APIOncologyHematologyAntibody-Drug Conjugate (ADC)Monoclonal Antibody (mAb)
MabPlex
Unclaimed · public records
CDMO · ADC / Bioconjugation, Drug Substance: Biologics, Cell Line / Strain Development
ADC / BioconjugationDrug Substance: BiologicsCell Line / Strain DevelopmentOncologyHematologyAntibody-Drug Conjugate (ADC)Monoclonal Antibody (mAb)
Merck KGaA (MilliporeSigma / Sigma-Aldrich CTDMO)
Unclaimed · public records
CRO & CDMO · Viral Vector Manufacturing, Cell Therapy Manufacturing, mRNA / RNA Manufacturing
Viral Vector ManufacturingCell Therapy ManufacturingmRNA / RNA ManufacturingOncologyHematologyGene Therapy (AAV / Viral Vector)Cell Therapy (CAR-T / NK / TIL)
VectorBuilder
Unclaimed · public records
CRO & CDMO · Viral Vector Manufacturing, Plasmid DNA Manufacturing, Process Development
Viral Vector ManufacturingPlasmid DNA ManufacturingProcess DevelopmentOncologyRare / Orphan DiseaseGene Therapy (AAV / Viral Vector)Plasmid DNA
Pharmaron (Biologics / CGT)
Unclaimed · public records
CRO & CDMO · Viral Vector Manufacturing, Plasmid DNA Manufacturing, Cell Therapy Manufacturing
Viral Vector ManufacturingPlasmid DNA ManufacturingCell Therapy ManufacturingOncologyRare / Orphan DiseaseGene Therapy (AAV / Viral Vector)Plasmid DNA
SK pharmteco
Unclaimed · public records
CDMO · Viral Vector Manufacturing, Plasmid DNA Manufacturing, Cell Therapy Manufacturing
Viral Vector ManufacturingPlasmid DNA ManufacturingCell Therapy ManufacturingOncologyHematologyGene Therapy (AAV / Viral Vector)Cell Therapy (CAR-T / NK / TIL)
The Center for Breakthrough Medicines
Unclaimed · public records
CDMO · Viral Vector Manufacturing, Cell Therapy Manufacturing, Plasmid DNA Manufacturing
Viral Vector ManufacturingCell Therapy ManufacturingPlasmid DNA ManufacturingOncologyHematologyGene Therapy (AAV / Viral Vector)Cell Therapy (CAR-T / NK / TIL)
ElevateBio BaseCamp
Unclaimed · public records
CDMO · Cell Therapy Manufacturing, Viral Vector Manufacturing, Process Development
Cell Therapy ManufacturingViral Vector ManufacturingProcess DevelopmentOncologyHematologyCell Therapy (CAR-T / NK / TIL)Gene Therapy (AAV / Viral Vector)
RoslinCT
Unclaimed · public records
CDMO · Cell Therapy Manufacturing, Process Development, Analytical Development
Cell Therapy ManufacturingProcess DevelopmentAnalytical DevelopmentHematologyOncologyCell Therapy (CAR-T / NK / TIL)Gene Editing (CRISPR-based)
Minaris Advanced Therapies
Unclaimed · public records
CDMO · Cell Therapy Manufacturing, Viral Vector Manufacturing, Process Development
Cell Therapy ManufacturingViral Vector ManufacturingProcess DevelopmentOncologyHematologyCell Therapy (CAR-T / NK / TIL)Gene Therapy (AAV / Viral Vector)
Cellipont Bioservices
Unclaimed · public records
CDMO · Cell Therapy Manufacturing, Process Development, Analytical Development
Cell Therapy ManufacturingProcess DevelopmentAnalytical DevelopmentOncologyHematologyCell Therapy (CAR-T / NK / TIL)
Genezen
Unclaimed · public records
CDMO · Viral Vector Manufacturing, Cell Therapy Manufacturing, Plasmid DNA Manufacturing
Viral Vector ManufacturingCell Therapy ManufacturingPlasmid DNA ManufacturingOncologyHematologyGene Therapy (AAV / Viral Vector)Cell Therapy (CAR-T / NK / TIL)
Aldevron (Danaher)
Unclaimed · public records
CDMO · Plasmid DNA Manufacturing, mRNA / RNA Manufacturing, Process Development
Plasmid DNA ManufacturingmRNA / RNA ManufacturingProcess DevelopmentOncologyHematologyPlasmid DNAmRNA / saRNA
National Resilience
Unclaimed · public records
CDMO · Viral Vector Manufacturing, Cell Therapy Manufacturing, mRNA / RNA Manufacturing
Viral Vector ManufacturingCell Therapy ManufacturingmRNA / RNA ManufacturingOncologyHematologyGene Therapy (AAV / Viral Vector)Cell Therapy (CAR-T / NK / TIL)
Oxford Biomedica
Unclaimed · public records
CDMO · Viral Vector Manufacturing, Plasmid DNA Manufacturing, Process Development
Viral Vector ManufacturingPlasmid DNA ManufacturingProcess DevelopmentOncologyHematologyGene Therapy (AAV / Viral Vector)Cell Therapy (CAR-T / NK / TIL)
WuXi Advanced Therapies
Unclaimed · public records
CRO & CDMO · Viral Vector Manufacturing, Cell Therapy Manufacturing, Plasmid DNA Manufacturing
Viral Vector ManufacturingCell Therapy ManufacturingPlasmid DNA ManufacturingOncologyHematologyGene Therapy (AAV / Viral Vector)Cell Therapy (CAR-T / NK / TIL)
Catalent
Unclaimed · public records
CDMO · Viral Vector Manufacturing, Cell Therapy Manufacturing, Plasmid DNA Manufacturing
Viral Vector ManufacturingCell Therapy ManufacturingPlasmid DNA ManufacturingOncologyHematologyGene Therapy (AAV / Viral Vector)Cell Therapy (CAR-T / NK / TIL)
AGC Biologics
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
Samsung Biologics
Unclaimed · public records
CDMO · Cell Line / Strain Development, Process Development, Analytical Development
Cell Line / Strain DevelopmentProcess DevelopmentAnalytical DevelopmentOncologyImmunology & InflammationMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
Thermo Fisher Scientific (Patheon)
Unclaimed · public records
CRO & CDMO · Process Development, Drug Substance: Small Molecule / API, Analytical Development
Process DevelopmentDrug Substance: Small Molecule / APIAnalytical DevelopmentOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
Piramal Pharma Solutions
Unclaimed · public records
CRO & CDMO · Hit-to-Lead, Lead Optimization, Medicinal & Synthetic Chemistry
Hit-to-LeadLead OptimizationMedicinal & Synthetic ChemistryOncologyCNS / NeurologySmall MoleculeAntibody-Drug Conjugate (ADC)
WuXi STA (WuXi AppTec)
Unclaimed · public records
CRO & CDMO · Medicinal & Synthetic Chemistry, Process Development, Analytical Development
Medicinal & Synthetic ChemistryProcess DevelopmentAnalytical DevelopmentOncologyHematologySmall MoleculePeptide
Lonza
Unclaimed · public records
CRO & CDMO · Drug Substance: Small Molecule / API, Process Development, Analytical Development
Drug Substance: Small Molecule / APIProcess DevelopmentAnalytical DevelopmentOncologyRare / Orphan DiseaseSmall MoleculeAntibody-Drug Conjugate (ADC)
TD2 (Translational Drug Development)
Unclaimed · public records
CRO · In Vitro Pharmacology, Biomarker Discovery & Development, PK/PD & Modeling
In Vitro PharmacologyBiomarker Discovery & DevelopmentPK/PD & ModelingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
InnoSer Laboratories
Unclaimed · public records
CRO · In Vitro Pharmacology, Biomarker Discovery & Development, PK/PD & Modeling
In Vitro PharmacologyBiomarker Discovery & DevelopmentPK/PD & ModelingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Biocytogen
Unclaimed · public records
CRO · In Vitro Pharmacology, Target ID & Validation, Biomarker Discovery & Development
In Vitro PharmacologyTarget ID & ValidationBiomarker Discovery & DevelopmentOncologyHematologyMonoclonal Antibody (mAb)Bispecific / Multispecific Antibody
ProQinase (Reaction Biology Europe)
Unclaimed · public records
CRO · In Vitro Pharmacology, Assay Development & Screening, Biomarker Discovery & Development
In Vitro PharmacologyAssay Development & ScreeningBiomarker Discovery & DevelopmentOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
XenTech
Unclaimed · public records
CRO · In Vitro Pharmacology, Biomarker Discovery & Development, PK/PD & Modeling
In Vitro PharmacologyBiomarker Discovery & DevelopmentPK/PD & ModelingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
EPO Berlin-Buch (Experimental Pharmacology & Oncology)
Unclaimed · public records
CRO · In Vitro Pharmacology, Biomarker Discovery & Development, PK/PD & Modeling
In Vitro PharmacologyBiomarker Discovery & DevelopmentPK/PD & ModelingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
The Jackson Laboratory (JAX)
Unclaimed · public records
CRO · In Vitro Pharmacology, Biomarker Discovery & Development, Target ID & Validation
In Vitro PharmacologyBiomarker Discovery & DevelopmentTarget ID & ValidationOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Oncodesign Services
Unclaimed · public records
CRO · In Vitro Pharmacology, DMPK / ADME, Bioanalytical Services
In Vitro PharmacologyDMPK / ADMEBioanalytical ServicesOncologyImmunology & InflammationSmall MoleculeMonoclonal Antibody (mAb)
Reaction Biology
Unclaimed · public records
CRO · Assay Development & Screening, In Vitro Pharmacology, Target ID & Validation
Assay Development & ScreeningIn Vitro PharmacologyTarget ID & ValidationOncologyImmunology & InflammationSmall MoleculePROTAC / Targeted Protein Degrader
Champions Oncology
Unclaimed · public records
CRO · In Vitro Pharmacology, Biomarker Discovery & Development, Assay Development & Screening
In Vitro PharmacologyBiomarker Discovery & DevelopmentAssay Development & ScreeningOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Crown Bioscience
Unclaimed · public records
CRO · In Vitro Pharmacology, Biomarker Discovery & Development, Assay Development & Screening
In Vitro PharmacologyBiomarker Discovery & DevelopmentAssay Development & ScreeningOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Charles River Laboratories
Unclaimed · public records
CRO & CDMO · GLP Toxicology, Safety Pharmacology, Genetic Toxicology
GLP ToxicologySafety PharmacologyGenetic ToxicologyOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
TFS HealthScience
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Cytel
Unclaimed · public records
CRO · Biostatistics & Statistical Programming, Clinical Data Management, Clinical Operations
Biostatistics & Statistical ProgrammingClinical Data ManagementClinical OperationsOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Precision for Medicine
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
WuXi Clinical
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Tigermed
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Celerion
Unclaimed · public records
CRO · Phase 1 / Early Clinical Unit, Clinical Operations, Bioanalytical Services
Phase 1 / Early Clinical UnitClinical OperationsBioanalytical ServicesOncologyCNS / NeurologySmall MoleculeMonoclonal Antibody (mAb)
Emmes
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Novotech
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Premier Research
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Veristat
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Caidya
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Allucent
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
PSI CRO
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Worldwide Clinical Trials
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Syneos Health
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Medpace
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Fortrea
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
PPD (Thermo Fisher Scientific)
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
Parexel
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
ICON plc
Unclaimed · public records
CRO · Clinical Operations, Phase 1 / Early Clinical Unit, Clinical Data Management
Clinical OperationsPhase 1 / Early Clinical UnitClinical Data ManagementOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
IQVIA
Unclaimed · public records
CRO · Clinical Operations, Clinical Data Management, Biostatistics & Statistical Programming
Clinical OperationsClinical Data ManagementBiostatistics & Statistical ProgrammingOncologyHematologySmall MoleculeMonoclonal Antibody (mAb)
What kind of CRO work does a Hematology program need?
Hematology covers a wide spread of biology, from aggressive leukemias and lymphomas to multiple myeloma, myelodysplastic syndromes, and the non-malignant side: hemophilia and other bleeding disorders, sickle cell disease, thalassemia, and the immune cytopenias. The outsourced work changes a lot across that range, but the common thread is that almost everything keys off blood and bone marrow, which forces a set of capabilities a generalist oncology or immunology shop may not have on hand.
On the discovery and preclinical side, the models are the differentiator. Disseminated leukemia models built from cell lines or patient-derived xenografts, bone-marrow engraftment readouts, humanized mice for testing T-cell engagers and CAR constructs, and the flow cytometry panels to track those grafts are routine asks. Hematology lives on flow: immunophenotyping by CD markers, measurable residual disease (MRD) by multiparameter flow or next-generation sequencing, and the assay validation behind both. For the bleeding and red-cell disorders the bench work looks different again, coagulation factor assays, thrombin generation, hemoglobin and hemolysis readouts, so matching the supplier to the specific disease subset matters more here than in many therapeutic areas.
Clinically, hematology trials carry their own operational weight. Endpoints like complete response, MRD negativity, overall and progression-free survival, and transfusion independence drive the protocol, and the data flows through specialist central labs and pathology review. Patient access is the constant constraint: many hematologic malignancies are not common, and the rare benign disorders are rarer still, so a CRO that already has relationships with hematology-oncology centers and the right academic sites is worth far more than one promising to build that network from scratch. On the CDMO side, cell and gene therapy programs (CAR-T, gene-edited stem cells for sickle cell and beta-thalassemia) pull in apheresis logistics, GMP cell processing, and viral vector or editing supply, which is a different manufacturing world from a small-molecule kinase inhibitor.
- Discovery and preclinical: disseminated and PDX leukemia/lymphoma models, bone-marrow engraftment studies, humanized mice for immunotherapy, coagulation and red-cell assays for benign hematology
- Translational and biomarker: flow cytometry immunophenotyping, MRD by flow or NGS, cytogenetics and FISH, molecular panels (mutations, fusion transcripts), companion diagnostic development
- Clinical operations: hematology-experienced CRAs and medical monitors, access to hem-onc and transplant centers, protocols built around response, MRD, and survival endpoints
- Central lab and pathology: harmonized flow and MRD assays across sites, central hematopathology and bone-marrow review, specialty coagulation testing
- CMC and manufacturing: GMP supply for small molecules and biologics, plus apheresis, cell processing, and vector or gene-editing supply for cell and gene therapies
How do you choose a CRO for Hematology?
The first cut is real hematology experience in your specific subset, not therapeutic-area experience in general. A CRO that has run dozens of solid-tumor oncology trials may still be light on leukemia, and a leukemia specialist may have never touched a hemophilia program. Ask for completed programs in your disease (AML, DLBCL, multiple myeloma, sickle cell, whatever it is) and check whether the people you would actually work with did that work, rather than trusting a company-level case study.
From there, the practical questions separate a strong partner from a frustrating one. Use this checklist when you compare suppliers:
- Therapeutic-area depth: documented programs in your exact hematologic indication and modality, with named scientists or medical monitors who have run them before
- Disease models and assays: the relevant in vivo model already validated in-house with historical control data, plus flow cytometry and MRD methods that hit the sensitivity your endpoint needs (for example MRD to 10^-5 or 10^-6)
- Patient access and site network: existing relationships with hematology-oncology, transplant, and academic centers, and realistic enrollment estimates for a population that is often small
- Regulatory track record: a clean GLP, GCP, or GMP inspection history appropriate to the work, and experience supporting hematology submissions to the FDA or EMA
- Data quality and standards: validated assays, CDISC-conformant clinical data, central hematopathology and flow review, and straight reporting of what failed as well as what worked
- Capacity and timeline: current queue and a milestone schedule, since a great lab booked solid for months can be slower than a good one with an open slot
Frequently asked questions
What makes hematology CRO work different from solid-tumor oncology?
The biology runs through blood and bone marrow, so the toolkit shifts. Preclinical models are often disseminated leukemia or engraftment models rather than subcutaneous tumors, and the core readouts are flow cytometry immunophenotyping and measurable residual disease (MRD) rather than tumor volume. Clinically, endpoints like complete response, MRD negativity, and transfusion independence drive the protocol, and central hematopathology and specialty coagulation labs do work a solid-tumor CRO may not offer. A supplier strong in solid-tumor oncology is not automatically a fit for leukemia, lymphoma, or the benign hematology disorders, so confirm experience in your specific subset.
Can one CRO cover both malignant and benign hematology?
Some can, but it is worth checking rather than assuming. Malignant hematology (leukemias, lymphomas, myeloma) and benign or classical hematology (hemophilia and other bleeding disorders, sickle cell disease, thalassemia, immune cytopenias) use different models, assays, and endpoints. A group built around MRD and survival in AML may have little depth in coagulation factor assays or transfusion-independence endpoints, and the reverse holds too. If your program spans both, you may need different suppliers for different pieces, which is exactly the case where contracting through one counterparty helps.
How important is patient access for a hematology trial?
Very, and it is usually the binding constraint on timeline. Many hematologic malignancies are uncommon, and the benign disorders rarer still, so enrollment depends heavily on whether the CRO already has relationships with hematology-oncology centers, transplant programs, and the academic sites that see these patients. A supplier with an established hematology site network and a credible, not optimistic, enrollment estimate is worth more than a lower bid from a CRO that would be building those relationships on your dollar.
What flow cytometry and MRD capabilities should a hematology supplier have?
Flow cytometry is foundational in hematology, so look for validated multiparameter immunophenotyping panels and MRD assays at the sensitivity your endpoint requires, commonly 10^-5 to 10^-6 by multiparameter flow or next-generation sequencing. For a multi-site trial you also want harmonized assays across a central lab so results stay comparable, plus central hematopathology and bone-marrow review. Ask whether the methods are already validated and inspection-ready, since standing up a new MRD assay mid-program adds time and risk to your most important readouts.
Does a CAR-T or gene therapy hematology program need a different kind of supplier?
Yes. Cell and gene therapy programs (CAR-T for blood cancers, gene-edited or gene-addition approaches for sickle cell disease and beta-thalassemia) pull in capabilities a small-molecule or antibody program does not: apheresis logistics, GMP cell processing, viral vector or gene-editing supply, and the analytics behind them. The preclinical work leans on humanized mouse models and biodistribution or persistence studies. On BioBridgeX you can filter for suppliers that have actually run programs in your modality rather than forcing a cell therapy onto a generalist set up for traditional small molecules.
How does sourcing hematology suppliers through BioBridgeX work?
BioBridgeX is a neutral marketplace. You describe the work (the hematologic indication, the modality, the services, the rough scope) and get matched with qualified CRO and CDMO suppliers who do that specific work, then compare them on capability, relevant experience, and transparent quotes. It is free for buyers, and suppliers pay a flat 2% fee, so there is no incentive to steer you toward a pricier lab. When a program needs several suppliers, a preclinical model lab, a central flow and MRD lab, a clinical operations CRO, you still compare them and contract directly with the ones you choose, in one place.
Source Hematology work with one contract
Compare transparent quotes from qualified Hematology CRO and CDMO vendors, then contract once. Free for buyers.
Compare quotes